TABLE 1.
Patients' characteristics in the entire population (N = 160) and according the Nab‐Paclitaxel plus Gemcitabine line of treatment.
| Characteristics | Overall (N=160) | Second line (N=111) | Third/fourth line (N=49) |
|---|---|---|---|
| AGE (years) | |||
| Median | 61 | 62 | 60 |
| Range | 31–84 | 31–84 | 38–79 |
| Sex—N (%) | |||
| Male | 101 (63.1) | 72 (65.9) | 29 (59.2) |
| Female | 59 (36.9) | 39 (35.1) | 20 (40.8) |
| ECOG PS—dN (%) | |||
| 0 | 57 (35.6) | 38 (32.2) | 19 (38.8) |
| 1 | 64 (40) | 48 (43.2) | 16 (32.6) |
| 2 | 39 (24.4) | 25 (22.5) | 14 (28.6) |
| Pancreatic tumor site—N (%) | |||
| Head | 87 (54.4) | 62 (55.9) | 25 (51.0) |
| Body‐tail | 73 (45.6) | 49 (44.1) | 24 (49.0) |
| Metastatic sites—N (%) | |||
| Liver | 113 (70.6) | 81 (75.7) | 32 (60.4) |
| Lymphnodes | 42 (26.2) | 32 (29.9) | 10 (18.9) |
| Lung | 38 (23.7) | 18 (16.8) | 20 (37.7) |
| Peritoneum | 33 (20.6) | 20 (18.7) | 13 (24.5) |
| Other | 15 (9.4) | 10 (9.3) | 5 (9.4) |
| Number of metastatic sites—N (%) | |||
| 1 | 93 (58.1) | 65 (58.6) | 28 (57.1) |
| ≥2 | 67 (41.9) | 46 (41.4) | 21 (42.9) |
| Biliary stent—N (%) | |||
| Yes | 38 (23.7) | 25 (22.5) | 13 (26.5) |
| No | 122 (76.3) | 86 (77.5) | 36 (73.5) |
| Derivative biliary surgery—N (%) | |||
| Yes | 13 (8.1) | 9 (8.1) | 4 (8.5) |
| No | 147 (91.9) | 102 (91.9) | 45 (91.8) |
| Radical surgery—N (%) | |||
| Yes | 42 (26.4) | 28 (25.2) | 14 (28.6) |
| No | 118 (73.8) | 83 (74.8) | 35 (71.4) |
| Adjuvant chemotherapy—N (%) | |||
| Yes | 30 (18.7) | 20 (18.0) | 10 (20.4) |
| No | 130 (81.3) | 91 (82.0) | 39 (79.6) |
| Number of previous lines—N (%) | |||
| 1 | 111 (69.4) | ||
| 2 | 42 (26.2) | ||
| >2 | 7 (4.4) | ||
| First line chemotherapy—N (%) | |||
| Gem‐based | 64 (40) | 35 (31.5) | 29 (59.2) |
| Of which Gem monotherapy | 7 | 5 | 2 |
| FOLFIRINOX (classic or modified) | 96 (60) | 76 (68.5) | 20 (40.8) |